Skip to main content

Table 1 Demographic and clinical characteristics in the total vaccinated cohort

From: Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

 

QIV

TIV-Vic

TIV-Yam

 

N = 3036

N = 1010

N = 610

Mean age, years (SD; median; range)

57.9 (17.7; 64.0; 18.0–92.0)

58.1 (17.8; 64.0; 18.0–92.0)

58.1 (17.9; 65.0; 18.0–90.0)

Sub-groups: mean age, years (SD, median)

43.5 (13.58; 44.0)

43.7 (13.84; 44.0)

43.5 (14.01; 46.0)

  18–64 years

72.3 (5.45; 71.0)

72.5 (5.53; 71.0)

72.4 (5.39; 72.0)

  ≥65 years

   

Male, n (%)

1291 (42.5)

462 (45.7)

267 (43.8)

Hispanic/Latino ethnicity, n (%)

134 (4.4)

47 (4.7)

25 (4.1)

Not Hispanic/Latino ethnicity, n (%)

2902 (95.6)

963 (95.3)

585 (95.9)

Geographic ancestry

2078 (68.4)

699 (69.2)

414 (67.9)

  European heritage / Caucasian

22 (0.7)

7 (0.7)

4 (0.7)

  Arabic/north American heritage / Caucasian

805 (26.5)

270 (26.7)

162 (26.5)

  Asian

106 (3.5)

26 (2.6)

21 (3.4)

  African heritage / African American

6 (0.2)

2 (0.2)

3 (0.5)

  American Indian or native Alaskan

2 (0.1)

0

0

  Native Hawaiian or other pacific islander

17 (0.6)

6 (0.6)

6 (1.0)

  Other

   

Medical history, n (%)

533 (17.56)

153 (15.15)

106 (17.38)

  Cardiovascular disease

457 (15.05)

129 (12.77)

89 (14.59)

  Diabetes

293 (9.65)

104 (10.30)

57 (9.34)

  Chronic respiratory disease

117 (3.85)

39 (3.86)

26 (4.26)

  Cancer

76 (2.50)

17 (1.68)

13 (2.13)

  Cerebrovascular disease

60 (1.98)

23 (2.28)

13 (2.13)

  Chronic hepatic disease

43 (1.42)

11 (1.09)

6 (0.98)

  Chronic renal disease

   

Received seasonal influenza vaccination in at least one of previous three seasons, n (%)

2395 (78.9)

788 (78.0)

483 (79.2)

Received A/H1N1pdm09 vaccination during the previous season

848 (27.9)

289 (28.6)

165 (27.0)

  1. QIV inactivated quadrivalent influenza vaccine, SD standard deviation, TIV-Vic inactivated trivalent influenza vaccine Victoria lineage B strain, TIV-Yam inactivated trivalent influenza vaccine Yamagata lineage B strain, Excluding hypertension.